Ophthalmologists may play a role in early Alzheimer diagnoses


Clues to diagnosis from patient and family histories, examination techniques.

Ophthalmologists may play a role in early Alzheimer diagnoses

Signs and symptoms of Alzheimer disease in the retina, optic nerve, and the more posterior afferent visual system in the temporal and parietal lobes may point physicians to a diagnosis of Alzheimer disease earlier than previously real­ized, according to Robert C. Sergott, MD.

Sergott, director of the Neuro-Ophthalmology Ser­vice at Wills Eye Hospital and founding director and CEO of the Annesley EyeBrain Center at Thomas Jefferson University in Philadelphia, Pennsylvania, pointed out the importance of awareness of often subtle signs and symptoms in patients 55 years and older, based on the possibility that treatments for Alzheimer disease may be available in the next sev­eral months. The availability of potential treatments to address early disease may sidetrack its current ability to destroy the brain and retinal and optic nerve function.

With diseases such as Alzheimer disease and Par­kinson disease, patients may present first to an oph­thalmologist rather than a neurologist because of the associated visual disturbances.

Pearls gleaned from a case

Sergott described a 68-year-old man who presented with progressive field constriction for 2 years and the inability to drive at night for approximately 1½ years. The patient described seeing oncoming lights when driving as starbursts.

Related: COVID-19: How neuro-ophthalmology is acclimating in the pandemic era

Constricted visual fields may be an initial pre­sentation as a possibility of Alzheimer disease. The differential diagnosis is large and includes retinal degenerations, quinine toxicity, central retinal artery occlusion, end-stage glaucoma or papilledema, conflu­ent optic disc drusen, bilateral occipital lobe infarc­tions, nonphysiologic response, and cognitive impair­ment on automated perimetry.

Sergott explained that visual field constriction implicates a visual field defect in the retina, optic nerve, or occipital lobe; the photophobia in the ret­ina; and night blindness and depth perception to a retinal or cortical issue. Consideration of the 3 loca­tions suggests that there may be more of a retinal or cortical problem, or both.

“Alzheimer disease affects them all, i.e., the retina, optic nerve, and the visual system posterior to the lateral geniculate,” he said.

Related: A study shows Alzheimer’s disease biomarkers in the vitreous

The patient’s history was positive for prostate can­cer and basal and squamous cell cancers, without metastases; hypertension; and hyperlipidemia.

“A rule to live by in neuro-ophthalmology is to determine if the patient’s problem at hand is caused by the cancer recurrence, especially breast cancer, or cancer therapy,” Sergott emphasized.

The patient’s ocular examination was unremark­able with 20/40 vision bilaterally. Interestingly, the patient could see only the test Ishihara plate although he had no history of color blindness. The acquired loss of color vision could be in the cones, optic nerve, or cortical system.

“This provides a subtle hint of an afferent visual problem. Color vision measures contrast sensitivity,” he said. “Using low-contrast visual acuity [VA], a deficit worse than 20/40 might be identified.”

Optical coherence tomography imaging was unremarkable but showed slight flattening, with the fovea-macular contour slightly broadened. Fundus autofluorescence also showed no striking abnormal­ity suggestive of early Alzheimer disease.

Multifocal electroretinography (ERG), however, showed an almost isoelectric tracing in the right eye despite 20/40 vision. In the left eye, multifocal ERG abnormalities were present but not as pronounced as the right eye.

Related: Infiltrative optic neuropathy in a patient with esophageal adenocarcinoma

Cranial MRI showed nonspecific changes and that paraneoplastic autoantibodies and the lumbar puncture cerebrospinal fluid profile were negative.

Automated perimetry showed an inferior quadran­tanopia in the left eye and a more subtle defect in the right eye. This localization pattern is in the right parietal temporal lobe.

“From this testing, we know that this patient has brain disease in the right parietal temporal lobe,” Sergott explained. “The multifocal ERG results indi­cated the presence of retinal disease. This proved to be an extensive process in the visual system.”

In addition to the constricted visual fields, color vision deficit, and abnormal ERG, the patient’s his­tory showed dissatisfaction with the results of cata­ract surgery despite 20/40 bilateral VA and a depth perception of only 40 seconds of arc.

“One reason for dissatisfaction postoperatively with a good Snellen VA may be Alzheimer disease,” he said. “The root of the dissatisfaction may be subtle problems with difficulty reading and finding words and mild short-term memory loss.”

Other clues are that the patient never arrived alone at appointments and often did not answer questions directed to them, Sergott added.

Dementia classifications

Patients who present with predominantly visual symptoms may have posterior cortical atrophy.

However, Sergott cautioned physicians about rec­ognizing patients who present with mildly disrupted memory and functioning, which may point to other findings suggestive of a more global deficit of visual processing. These may include a progressive decline in visuospatial, visual perception, and liter­acy skills that appear in patients who are on average 50 to 65 years of age.

Experts disagree about whether posterior cortical atrophy is a pure form of Alzheimer disease or a separate entity. Lewy body dementia and prion disease also may have similar visual symptoms.

Related: Technology "perfect" for pediatric neuro-ophthalmology diagnoses

Practical guidelines to ophthalmic presentations

Sergott prioritized the various ophthal­mologic findings when ophthalmologists are confronted with patients similar to the patient under discussion.

The ophthalmic presentations of Alzheimer disease include the unhappy patient with good VA after cataract sur­gery and in patients not having had recent cataract surgery, loss of color vision, depth perception, and photoreceptor dysfunction manifesting as glare and night blindness.

Sergott said he believes that the multifo­cal ERG may be the most sensitive test to identify retinal abnormalities in patients with dementia syndromes.

Related: Targeting neurodegenerative diseases with risuteganib as treatment therapy

He also advised physicians to be alert to patients with visual field defects who have trouble with the automated perime­try test, especially with repeated attempts.

Patients may also present with a hom­onymous hemianopsia a normal MRI scan. This clinical presentation should alert ophthalmologists and neurologists to the possibility of Alzheimer disease.

“When such patients present, Alzheimer disease should be suspected. Hopefully, during 2021 some treatments will become available,” he said. “[As with] most treat­ments, they will work better the sooner they are instituted before the disease destroys most of the brain and a large segment of the retinal and optic nerve function. Oph­thalmologists may be the key to get the diagnostic process moving.”

e: rcs220@comcast.net
This article is adapted from Sergott’s presentation at the Ohio Ophthalmological Society’s virtual annual meeting in February. He has no financial interest in this subject matter.

Related Content: Imaging | Ophthalmology | Wet AMD Viewpoint | Retina in 2020

Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.